
Pathogenic TDP‐43 accelerates the generation of toxic exon1 HTT in Huntington’s disease knock‐in mice
Brief intro:
- Author: Dazhang Bai, Fuyu Deng, Qingqing Jia, Kaili Ou, Xiang Wang, Junqi Hou, Longhong Zhu, Mingwei Guo, Su Yang, Guohui Jiang, Shihua Li, Xiao-Jiang Li, Peng Yin
- Journal: Aging Cell
- Doi: https://www.doi.org/10.1111/acel.14325
- Publication Date: 2024 Aug 26
Products/Services used in the paper
Quotation shows PackGene:AAV9-UBC vector for expressing ΔNLS-TDP-43 or WT-TDP-43 under the UBC promoter was purchased from Guangzhou Packgene Biotechnology Ltd.
Research Field:Huntington's disease
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:mice
Abstract
Huntington's disease (HD) is caused by a CAG repeat expansion in exon1 of the HTT gene that encodes a polyglutamine tract in huntingtin protein. The formation of HTT exon1 fragments with an expanded polyglutamine repeat has been implicated as a key step in the pathogenesis of HD. It was reported that the CAG repeat length-dependent aberrant splicing of exon1 HTT results in a short polyadenylated mRNA that is translated into an exon1 HTT protein. Under normal conditions, TDP-43 is predominantly found in the nucleus, where it regulates gene expression. However, in various pathological conditions, TDP-43 is mislocalized in the cytoplasm. By investigating HD knock-in mice, we explore whether the pathogenic TDP-43 in the cytoplasm contributes to HD pathogenesis, through expressing the cytoplasmic TDP-43 without nuclear localization signal. We found that the cytoplasmic TDP-43 is increased in the HD mouse brain and that its mislocalization could deteriorate the motor and gait behavior. Importantly, the cytoplasmic TDP-43, via its binding to the intron1 sequence (GU/UG)n of the mouse Htt pre-mRNA, promotes the transport of exon1-intron1 Htt onto ribosome, resulting in the aberrant generation of exon1 Htt. Our findings suggest that cytoplasmic TDP-43 contributes to HD pathogenesis via its binding to and transport of nuclear un-spliced mRNA to the ribosome for the generation of a toxic protein product.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
